News

Par begins shipping generic Exforge tabs

BY Ryan Chavis

WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths. The tablets are the generic version of Exforge from Novartis and are used to treat hypertension. 
 
The tablets also are indicated to lower blood pressure in patients not controlled on monotherapy and as initial therapy in patients who likely need multiple drugs to achieve their blood-pressure goals, the company stated. U.S. sales of Exforge totaled approximately $422 million, according to IMS Health data. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Salix, Progenics announce FDA approval for Relistor

BY Ryan Chavis

RALEIGH, N.C. and TARRYTOWN, N.Y. — Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. The drug currently is the only available medication approved for treating opioid-induced constipation at the cause without interfering with the properties of the opioid, the companies said. 
 
“Frequently, opioid analgesics are prescribed to manage pain in patients suffering from chronic conditions. Unfortunately, the use of an opioid can result in debilitating constipation for a significant number of these patients,” said Bill Forbes, EVP, medical, research and development and chief development officer, Salix. “The approval and availability of Relistor for treating the underlying cause of OIC provides an important and welcomed advancement for many patients who experience constipation while taking opioids for chronic non-cancer pain.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Hamacher Resource Group names director of marketing

BY Michael Johnsen

WAUKESHA, Wis. — Hamacher Resource Group on Tuesday announced the addition of Cari Sass as director of marketing. Sass is leading HRG’s marketing team and working with the directors of business development and national accounts to strengthen relationships with clients and prospects. As part of the leadership team, she is helping to ensure HRG solutions meet the needs of their target audiences. Sass also will be responsible for expanding, strengthening and protecting the integrity of the HRG brand.
 
Sass previously served as director of marketing for a prominent Milwaukee-based architectural firm for 14 years, and brings with her a strategic yet visionary approach to marketing services that will serve the diverse manufacturer, retail, wholesale and technology organizations who seek HRG’s expertise on marketing solutions that will make an impact in the health, beauty and wellness marketplace.
 
“Cari’s background and management style make her a great fit with our leadership team,” said Dawn Vogelsang, HRG president. “Her contributions to corporate marketing planning and communications, creative direction and guidance of new product and service development will help take our marketing efforts to new heights.” 
 
“I am very excited for this new opportunity,” Sass said. “It is an honor to join a company so highly regarded within the industry, and I am looking forward to working with leadership and the marketing team to refine and develop new and innovative solutions to best serve our clients and shape the health, beauty and wellness consumer experience at retail.” 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?